Vertex has reported a phase 2 win that still dented confidence in its pain prospect suzetrigine. The trial linked the ...

When manifesting your wildest dreams, there’s always a need for a dash of delusion. Like a kid who believes in magic, it’s ...

Can't-Miss Play: Punt-block gone wrong! Cowboys' block leads to Bengals' recovery at critical moment ...

Vertex Pharmaceuticals said on Thursday its experimental non-opioid drug met the main goal of a mid-stage study but showed ...

Although the primary endpoint was not met in a phase 2 study of women who used CBD before a scan, researchers say CBD does ...

Therapy candidate LYT-100 worked better than Esbriet, with fewer side effects, to slow lung function decline in IPF patients, ...

A recent New York Times story described a new fad: "microdosing" GLP-1 anti-obesity drugs like semaglutide (Ozempic, Wegovy) ...

A systematic review identified 13 strategies, including patient and provider education, empathetic communication, and shared ...

Antibodies can improve the rehabilitation of people with acute spinal cord injury. Researchers have investigated this with promising results. For the first time, it was possible to identify patient ...

As legal restrictions loosen, scientists are investigating long held beliefs that cannabis has few side effects and can ...

Hannah joined The Scientist as an assistant editor in 2023. She earned her PhD in neuroscience from the University of Washington in 2017 and completed the Dalla Lana Fellowship in Global Journalism in ...